Telerx Marketing
Telerx Marketing is recorded as a service provider in 8 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 8 of 8 trials · Latest update first
Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) s.c. in doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg once weekly versus placebo in participants with type 2 diabetes as add on to once-daily basal insulin with or without metformin
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Operational learnings available1 trial-level finding · Read insights
- The study was conducted in China, Japan, Serbia, Slovakia, South Africa, and the United States of America.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 2, Open-Label, 156-week Trial to Investigate the Efficacy, Safety and Tolerability of Once Weekly Navepegritide and Lonapegsomatropin in Children with Achondroplasia
Sponsor Ascendis Pharma Growth Disorders A/S
- Start (EU)
- Latest update
- Estimated end
Adjustable brodalumab dosage regimen compared with standard brodalumab treatment for 52 weeks in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight; ADJUST - Phase 4 – efficacy, A randomised, double-blind, controlled, parallel group, multi-centre trial
Sponsor Leo Pharma A/S
- Start (EU)
- Latest update
- Estimated end
B7981032 - A PHASE 3 OPEN-LABEL, MULTI-CENTER, LONG-TERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF-06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
Open-Label Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Povetacicept in Subjects with Autoimmune Cytopenias (RUBY-4)
Sponsor Alpine Immune Sciences Inc.
- Start (EU)
- Latest update
- Estimated end
C1071015 - ELRANATAMAB POST TRIAL ACCESS: AN OPEN-LABEL, SINGLE-ARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER-SPONSORED ELRANATAMAB CLINICAL STUDIES
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
An open label, long-term extension study to evaluate the safety and efficacy of CRN00808 in subjects with acromegaly (ACROBAT ADVANCE)
Sponsor Crinetics Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
LP0162-1335: A single (assessor) blinded, randomized, parallel-group, monotherapy trial to evaluate the pharmacokinetics and safety of tralokinumab in children (age 6 to <12 years) with moderate to-severe atopic dermatitis. - TRAPEDS 1 (TRAlokinumab PEDiatric trial no. 1).
Sponsor Leo Pharma A/S
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Telerx Marketing?
The 2026-10-09 snapshot links Telerx Marketing to 8 distinct CTIS trials. Recorded services include Safety reporting & pharmacovigilance, AE Case Processing and Responsible Person for EudraVigilance, Emergency unblinding, Emergency unblinding and urgent medical coverage service, among 8 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Telerx Marketing?
The most frequently recorded therapeutic areas are Endocrinology, Genetic and Congenital Disorders, Metabolic Disorders, Musculoskeletal. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Telerx Marketing conducted?
The linked trials record locations in 15 countries, including Germany, Spain, Czechia, France, Greece. These are trial locations, not confirmed office locations or countries where Telerx Marketing delivered services.
What can this page tell me about Telerx Marketing's trial experience?
Browse 8 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Telerx Marketing. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Telerx Marketing Inc.